Mirabella (Ethinylestradiol, Gestodene)

Ethinylestradiol is a synthetic estrogen that binds to estrogen receptors, suppressing the release of follicle‑stimulating hormone from the pituitary gland. This inhibition prevents the development of a dominant follicle, contributing to the overall contraceptive effect when combined with Gestodene.

The dosage regimen for Mirabella is determined by the prescribing clinician. Typically, it is taken as one tablet daily at the same time each day, but the exact schedule and any missed‑dose instructions are individualized for each patient.

Mirabella is contraindicated during pregnancy and should not be started in women who are already pregnant. While limited data exist for breastfeeding, most guidelines advise caution and suggest alternative contraception methods unless the benefits outweigh potential risks.

To order Mirabella, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies, and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including any cold‑chain requirements), and necessary import documentation.

Mirabella contains Ethinylestradiol and Gestodene, a low‑dose estrogen‑progestin combination that offers efficacy comparable to other COCs. Differences lie mainly in the specific progestin used, which can influence side‑effect profiles such as acne improvement or lipid changes, allowing clinicians to tailor choices to individual patient needs.

Mirabella tablets should be stored at ambient temperature, below 25 °C, in the original container to protect them from moisture and light. Keep the product out of reach of children and avoid storing in areas with high humidity or direct sunlight.

Mirabella is taken orally as a tablet. Patients should swallow one tablet with water at the same time each day, preferably with food to reduce gastrointestinal discomfort. Consistent daily intake maintains hormone levels needed for effective contraception.

The most serious risks include venous thromboembolism, pulmonary embolism, stroke, myocardial infarction, and severe hypertension. These events are rare but can be life‑threatening, especially in women with pre‑existing cardiovascular risk factors, smoking habits, or a history of clotting disorders.

Mirabella is contraindicated in women who are pregnant, have a history of thromboembolic disorders, uncontrolled hypertension, severe liver disease, known or suspected breast cancer, or are smokers over the age of 35. It should also be avoided in individuals with known hypersensitivity to any component of the tablet.